Skip to main content

Table 1 Clinicopathologic features and TGF-β expression

From: Co-expression of parathyroid hormone related protein and TGF-beta in breast cancer predicts poor survival outcome

 

TGF-β positive No. (%)

TGF-β negative No. (%)

χ2

P value

Age

    

 ≤55

156 (56.9 %)

111 (49.8 %)

2.534

0.111

 >55

118 (43.1 %)

112 (50.2 %)

  

Tumor size

    

 ≤2 cm

137 (50.0 %)

141 (63.2 %)

8.729

0.003

 >2 cm

137 (50.0 %)

82 (36.8 %)

  

Skin involvementa

    

 No

229 (83.6 %)

190 (85.2 %)

0.245

0.620

 Yes

45 (16.4 %)

33 (14.8 %)

  

LN metastasis

    

 No

154 (57.5 %)

148 (67.9 %)

5.556

0.018

 Yes

114 (42.5 %)

70 (32.1 %)

  

 Unknown

6

5

  

Histologic grade

    

 ≤II

182 (67.7 %)

169 (78.2 %)

6.710

0.01

 >II

87 (32.3 %)

47 (21.8 %)

  

 Unknown

5

7

  

Clinical stage

    

 I

91 (33.2 %)

104 (46.6 %)

9.329

0.009

 II

128 (46.7 %)

82 (36.8 %)

  

 III

55 (20.1 %)

37 (16.6 %)

  

ER

    

 (−)

75 (28.7 %)

59 (27.6 %)

0.079

0.779

 (+)

186 (71.3 %)

155 (72.4 %)

  

 Unknown

13

9

  

HER-2

    

 (−)

94 (38.7 %)

83 (41.7 %)

0.417

0.518

 (+)

149 (61.3 %)

116 (58.3 %)

  

 Unknown

31

24

  

Tumor type

    

 IDCb

234 (85.4 %)

189 (84.8 %)

0.041

0.840

 Non-IDCc

40 (14.6 %)

34 (15.2 %)

  
  1. askin involvement: edema, redness, nodularity, or ulceration
  2. bIDC, invasive ductal carcinoma
  3. cNon-IDC: invasive lobular carcinoma, mucinous or colloid carcinoma, medullary carcinoma, metaplastic carcinoma